Glenmark's new generic gets FDA nod
19 August 2015 | News | By BioSpectrum Bureau
Glenmark's new generic gets FDA nod
The drug is the generic version of Yaz Tablets of Bayer HealthCare Pharmaceuticals
Glenmark Pharmaceuticals(Glenmark) has been granted final approval by the United States Food & Drug Administration (US FDA) for Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.02 mg. The drug is the generic version of Yaz Tablets of Bayer HealthCare Pharmaceuticals (Bayer).
Glenmark plans to commence shipping of Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.02 mg immediately.
According to IMS Health sales data for the 12 month period ending June 2015, the Yaz market achieved annual sales of approximately $170.1 million.
